Development of a transdermal gel for reversible male contraception
- PMID: 39862947
- PMCID: PMC11995303
- DOI: 10.1016/j.contraception.2025.110830
Development of a transdermal gel for reversible male contraception
Abstract
While there are several easy-to-use reversible female contraceptives, little is available for men. Introduction of novel, cost-effective male contraceptives could have important downstream global health and economic benefits. Currently, nearly half of all pregnancies globally are unintended, with many resulting in unsafe abortions, a significant burden for women and families in many countries. Available reversible options for male contraception include male condoms or withdrawal, both with high typical use failure rates, and vasectomy, which is not easily reversible. Advanced methods of male hormonal contraception include combinations of progestin and androgen, generally testosterone itself. Administration of these steroids results in the suppression of gonadotropins leading to the suppression of sperm production with full reversibility within a few months. Importantly, the exogenous androgen replaces the suppressed endogenous testosterone, minimizing side effects for the user. Using the skin to deliver steroids in the systemic circulation is a well-accepted concept both for the treatment of hypogonadism and contraception. A transdermal gel delivering Nestorone (segesterone acetate) and testosterone is under development and is leading the way in advancing novel, self-delivered methods of male hormonal contraception.
Keywords: Androgen; Male hormonal contraception; Nestorone; Semen analysis; Testosterone; Transdermal gel.
Copyright © 2025 Elsevier Inc. All rights reserved.
References
-
- Guttmacher Institute: unintended pregnancy in the United States: Fact Sheet March 2022. - https://www.guttmacher.org/fact-sheet/induced-abortion-worldwide
-
- Rossen LM, Hoyert D, Branum AM. US Trends in Maternal Mortality by Racial and Ethnic Group. JAMA. 2023; 330(18):1799–1800. doi: 10.1001/jama.2023.17547. https://pubmed.ncbi.nlm.nih.gov/37962660/ - DOI - PMC - PubMed
-
- Kaur J, Rohini DV, Chang L, Gugliotti A, Kretschmer S. Assessment of demand for male contraceptives: A multi-country study. Andrology. 2024;12(7):1512–24. doi: 10.1111/andr.13726. Epub 2024 Aug 19. https://pubmed.ncbi.nlm.nih.gov/39158308/ - DOI - PubMed
-
- Nieschlag E, Nieschlag S. Why we need more methods for male contraception. Andrology. 2023;11(3):421–4. doi: 10.1111/andr.13343. Epub 2022 Dec 2. https://pubmed.ncbi.nlm.nih.gov/36415925/ - DOI - PubMed
-
- Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C; Hormonal Male Contraception Summit Group. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006; 367(9520):1412–20. doi: 10.1016/S0140-6736(06)68614-5. https://pubmed.ncbi.nlm.nih.gov/16650651/ - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
